MARKET

ADAP

ADAP

Adaptimmune
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.79
-0.20
-2.00%
After Hours: 9.79 0 0.00% 17:30 07/02 EDT
OPEN
9.70
PREV CLOSE
9.99
HIGH
10.19
LOW
9.39
VOLUME
696.39K
TURNOVER
--
52 WEEK HIGH
13.40
52 WEEK LOW
0.7090
MARKET CAP
1.47B
P/E (TTM)
-7.6893
1D
5D
1M
3M
1Y
5Y

Analyst Rating

Based on 8 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target

The average ADAP stock price target is 12.83 with a high estimate of 17.00 and a low estimate of 9.00.

EPS

ADAP News

More
Edited Transcript of ADAP earnings conference call or presentation 14-May-20 12:00pm GMT
Q1 2020 Adaptimmune Therapeutics PLC Earnings Call
Thomson Reuters StreetEvents · 06/23 15:26
Adaptimmune Therapeutics plc (ADAP) Shares March Higher, Can It Continue?
Zacks · 06/17 14:33
How Adaptimmune Therapeutics (ADAP) Stock Stands Out in a Strong Industry
Zacks · 06/17 13:52
Is Adaptimmune Therapeutics a Buy?
Motley Fool · 06/12 11:30
Why Adaptimmune Therapeutics Stock Crushed It in May
Motley Fool · 06/08 15:30
Adaptimmune Therapeutics plc Announces Closing of Public Offering of American Depositary Shares
GlobeNewswire · 06/04 15:45
Adaptimmune Therapeutics shares are trading higher after the company priced a 20.5 million ADS offering at $11 per ADS.
Prices 20.5M ADS Offering @$11/ADS
Benzinga · 06/02 13:06
Adaptimmune prices ADS offering at $11
Adaptimmune Therapeutics (NASDAQ:ADAP) has priced its public offering of 20.5M American Depositary Shares (“ADSs”) at $11.00/ADS, for expected gross procee
seekingalpha · 06/02 13:00

Industry

Biotechnology & Medical Research
+0.67%
Pharmaceuticals & Medical Research
+0.61%

Hot Stocks

Symbol
Price
%Change

About ADAP

Adaptimmune Therapeutics plc is a clinical-stage biopharmaceutical company. The Company is focused on cancer immunotherapy products based on its Specific Peptide Enhanced Affinity Receptor (SPEAR) T-cell platform. Its SPEAR T-cell platform enables it to identify cancer targets, find and genetically engineer T-cell receptors (TCRs) against those targets, and produce therapeutic candidates (SPEAR T-cells) for administration to patients. The Company engineers TCRs to increase the affinity to cancer specific peptides in order to destroy cancer cells in patients. The Company’s product pipeline includes ADP-A2M4, ADP-A2M4CD8, ADP-A2AFP and ADP-A2M10. Its ADP-A2M4 (MAGE-A4) SPEAR T-cell therapy is directed to a member of the MAGE family of cancer testis antigen expressed in a number of solid tumor cell types.
More

Webull offers kinds of Adaptimmune Therapeutics PLC - ADR stock information, including NASDAQ:ADAP real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ADAP stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ADAP stock methods without spending real money on the virtual paper trading platform.